In order to explore interactions between the tumor and immune system, PD-L1 and CD8 expression on tumor cells and/or immune cells was assessed using a dual immunofluorescence (IF) assay on surgically resected samples from 95 NSCLC patients. The gene discussed is CD8A; the disease is neoplasm.